Toxicity, quality of life outcomes, and dosimetric impact in phase III trial of hypofractionated or standard fractionated proton therapy for low-risk prostate cancer patients: PCG GU 002. This is an ...
New biomarker technology shows promising results for predicting the prognosis of patients with prostate cancer after radical prostatectomy. According to new research published in Cancers, the use of ...
The value of transperineal prostate apical zone biopsy in predicting urethral or apical margin status after radical prostatectomy in prostate cancer. This is an ASCO Meeting Abstract from the 2019 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results